Of the more than 13,000 children who survived acute respiratory distress syndrome (ARDS), there was a 30.0% probability of hospital readmission within 1 year, 50% of which are likely to occur ...

TOPLINE: Inhaled sedation with sevoflurane in patients with moderate to severe acute respiratory distress syndrome (ARDS) resulted in fewer ventilator-free days at 28 days and lower 90-day ...

Compared with those with ARDS alone, patients hospitalized with ARDS and PH were more likely to have: In-hospital mortality (36.8% vs 24.6%, adjusted OR 1.52, 95% CI 1.46-1.58) ...

As for which patients may benefit the most from simvastatin, ARDS is a heterogeneous syndrome, grouped more by clinical findings than by a deep understanding of pathophysiological processes. The ...

The Food and Drug Administration (FDA) has approved a phase 3 clinical trial to evaluate siltuximab (EUSA Pharma) plus standard of care in hospitalized patients with coronavirus disease 2019 ...

BioAegis Therapeutics. Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS ...

Among the 740 patients who were admitted to the ICU after cardiac surgery during baseline periods, ARDS developed in 38 (5.1%). In the periods between baseline and influenza seasons, ARDS ...

In ARDS, the circulating half-life of methylprednisolone (1 mg/kg) varies from 3.8 to 7.2 h, with greatly diminished effects (irrespective of dosage) expected after 24 to 36 h. [28, 34, 35 ...